Operator: Thank you. Our next question comes from the line of Joseph Schwartz with SVB Securities. Your line is now open.
Joseph Schwartz: Hi everyone. Thanks very much. Since we’re so close to the panel, I was wondering if you have seen the FDA’s briefing documents at this point, and if you can give us your gestalt about their tone so that we can be more prepared for what to expect?
Doug Ingram: Yes. As I’ve said we are 10 days away counting from the advisory committee meeting. I wanted to be very clear about this. What we’re all doing together right now is extraordinarily serious. It’s important to us and it’s important to our investors, but it is vastly more serious and important to the patients living with Duchenne muscular dystrophy. This is literally a potential life or death issue for them, so in regard to that we are going to be mission driven. And what that means to us is we’re going to stay very focused on prosecuting our BLA, preparing for our Adcom, we’re not going to discuss the Adcom or the briefing books or the regulatory process right now. We’re going to do – we’re going to get ready for, and in my humble opinion we’re going to do a brilliant job.
Sorry for putting a lot of pressure on you, Louise. We’re going to do a brilliant job of presenting what I believe to be the wealth of evidence that supports that, the conclusion that 9001 and the amounts made by this therapy is reasonably likely to predict clinical benefits. So in light of that and with all respect and apologies for not answering your question, I’m not going to answer your questions on the regulatory process through the Advisory Committee until after May 12th. And then we’re going to all come together and I’m going to be thrilled to talk about all of these issues with you.
Operator: Thank you. Our next question comes from the line of Zhiqiang Shu with Berenberg. Your line is now open.
Zhiqiang Shu: Good afternoon. Thanks for taking my questions. And maybe going back to the manufacturing ramp, talking to some expectations on how many patients, do you plan to treat for 9001 and secondly on 9003 growth program. And obviously you commented the Phase 3 will start in the second half of the year. Is there any possibility for accelerated approval pathway for this program as well? Thanks very much.
Doug Ingram: So answering the second question first, ultimately we will propose a form of accelerated approval for 9003. This is an ultrarare disease. We are the 9003 makes the native protein, the absence of which is the sole and exclusive cause of the demise, and ultimately the death of patients suffer from 9003. So certainly if we see great results in the confirmatory trial in the Phase 3 that we’re starting, we are going to propose an accelerated approval pathway. As to the first question we, I’m not going to provide numbers on, numbers of patients other than to say our goal is to treat every patient that’s amenable to this therapy, as quickly as reasonably possible. And so we’re preparing ourselves to have a robust launch.
Operator: Thank you. Our next question comes from the line of Gavin Clark-Gartner with Evercore ISI. Your line is now open.
Gavin Clark-Gartner: Hey, thanks for fitting me in. Just to follow-up on the LGMD2E question, what’s your base case assumption for the Phase 3 primary endpoint and trial design? When will you align with the FDA on this?
